AU2014225575A8 - Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same - Google Patents

Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same

Info

Publication number
AU2014225575A8
AU2014225575A8 AU2014225575A AU2014225575A AU2014225575A8 AU 2014225575 A8 AU2014225575 A8 AU 2014225575A8 AU 2014225575 A AU2014225575 A AU 2014225575A AU 2014225575 A AU2014225575 A AU 2014225575A AU 2014225575 A8 AU2014225575 A8 AU 2014225575A8
Authority
AU
Australia
Prior art keywords
stem cells
methods
hepatocellular carcinoma
same
high purity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014225575A
Other versions
AU2014225575A1 (en
Inventor
Andrew CORNFORTH
Craig T. FREDERICKSON
Gabriel Nistor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeoStem Oncology LLC
Original Assignee
NeoStem Oncology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/053850 external-priority patent/WO2014028274A1/en
Application filed by NeoStem Oncology LLC filed Critical NeoStem Oncology LLC
Publication of AU2014225575A1 publication Critical patent/AU2014225575A1/en
Publication of AU2014225575A8 publication Critical patent/AU2014225575A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The disclosure provides cancer stem cells, for use in stimulating immune response against a cancer, such as hepatocellular carcinoma (HCC). Methods for preparing and purifying the cancer stem cells are provided.
AU2014225575A 2013-03-07 2014-03-06 Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same Abandoned AU2014225575A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361774517P 2013-03-07 2013-03-07
US61/774,517 2013-03-07
AUPCT/US2013/053850 2013-08-06
PCT/US2013/053850 WO2014028274A1 (en) 2012-08-15 2013-08-06 Rapid method production high purity cancer stem cells and population of high purity cancer stem cells
PCT/US2014/021353 WO2014138455A1 (en) 2013-03-07 2014-03-06 Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same

Publications (2)

Publication Number Publication Date
AU2014225575A1 AU2014225575A1 (en) 2015-09-10
AU2014225575A8 true AU2014225575A8 (en) 2015-10-01

Family

ID=51491971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014225575A Abandoned AU2014225575A1 (en) 2013-03-07 2014-03-06 Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same

Country Status (7)

Country Link
EP (1) EP2964754A4 (en)
JP (1) JP2016510756A (en)
KR (1) KR20150139855A (en)
CN (1) CN105308177A (en)
AU (1) AU2014225575A1 (en)
CA (1) CA2903212A1 (en)
WO (1) WO2014138455A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI563085B (en) * 2014-08-29 2016-12-21 China Medidal University Hospital Dendritic cell tumor vaccine and preparation method thereof
WO2016048872A1 (en) * 2014-09-23 2016-03-31 Neostem Oncology, Llc Compositions, methods and kits used to determine potency of dendritic cells in cancer immunitherpay
CN105031632B (en) * 2015-06-16 2018-08-10 杭州优善生物科技有限公司 A kind of dendritic cell vaccine and the preparation method and application thereof
KR101634546B1 (en) 2015-10-05 2016-06-29 주식회사 현대케피코 Apparatus for controlling electronic continuously variable valve timing and method thereof
US20180355321A1 (en) * 2015-12-18 2018-12-13 Zeon Corporation Method for preparing adherent-type cells acclimated to suspension culture, method for inducing epithelial-mesenchymal transition in adherent-type epithelial cells, and use for methods
JP2019511919A (en) * 2016-02-23 2019-05-09 ブローディ，チャヤ Production of cancer stem cells and use thereof
CN106636366A (en) * 2016-11-25 2017-05-10 苏州首度基因科技有限责任公司 Gene detection kit for prognosing gastric cancer metastasis and use method of gene detection kit
KR101869518B1 (en) * 2018-03-28 2018-06-20 황인후 Method of Preparing Dendritic Cell Based Cancer Vaccine Using EMT-MET Plasticity in Pancreatic Cancer Stem Cells
CN111733136B (en) * 2020-06-29 2021-11-30 中山大学孙逸仙纪念医院 Method for improving separation efficiency of CD90posi cells
CN111909962A (en) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 Virus construct for treating liver cancer and application and construction method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110244501A1 (en) * 2006-08-02 2011-10-06 Biogen Idec Ma Inc. Cancer stem cells
US8129184B2 (en) * 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2010011893A1 (en) * 2008-07-24 2010-01-28 University Of Central Florida Research Foundation, Inc. Therapy targeting cancer stem cells
ES2711504T3 (en) * 2009-07-24 2019-05-06 Rhode Island Hospital Dendritic cell vaccines for tumors that express asparaginyl-beta-hydroxylase
CN102793912A (en) * 2011-05-26 2012-11-28 北京清美联创干细胞科技有限公司 Dendritic cell (DC) tumor vaccine and preparation method thereof

Also Published As

Publication number Publication date
CN105308177A (en) 2016-02-03
KR20150139855A (en) 2015-12-14
AU2014225575A1 (en) 2015-09-10
WO2014138455A1 (en) 2014-09-12
JP2016510756A (en) 2016-04-11
CA2903212A1 (en) 2014-09-12
EP2964754A1 (en) 2016-01-13
EP2964754A4 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
AU2014225575A8 (en) Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
HK1222121A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc ( nsclc )
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
IN2014CN03143A (en)
MX366804B (en) R-spondin translocations and methods using the same.
MX2013008390A (en) Preparation of metal-triazolate frameworks.
AU2014249346A8 (en) High purity ovarian cancer stem cells for active autologous immune therapy
MX2015009106A (en) Solid solution compositions and use in severe pain.
MX2015014431A (en) Gla monotherapy for use in cancer treatment.
PH12015500040A1 (en) Supercritical hydrolysis of biomass
MX2016014235A (en) Microbial ergothioneine biosynthesis.
MX2020010991A (en) Composition for controlled ovarian stimulation.
EP3641789A4 (en) Methods for producing regulatory immune cells and uses thereof
MX2016003653A (en) Papaya mosaic virus and virus-like particles in cancer therapy.
IN2014DN06104A (en)
MY191539A (en) Streptococcal vaccine
EP3016936A4 (en) Process for preparing clomazone, novel form and use of the same
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
IL246143A0 (en) Acid-solubilized copper-ammonium complexes and copper-zinc-ammonium complexes, compositions, preparations, methods, and uses
EP3086360A4 (en) Semiconductor element, method for producing same and aliphatic polycarbonate
MX357675B (en) Anti-jagged anitbodies and methods of use.
IN2014MU00455A (en)
MX2015010023A (en) Anti-cd83 antibodies and use thereof.
EP3030268A4 (en) Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 29 , NO 35 , PAGE(S) 5305 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME NEOSTEM ONCOLOGY, LLC, APPLICATION NO. 2014225575, UNDER INID (72) CORRECT THE CO-INVENTOR TO NISTOR, GABRIEL

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period